Medivir appoints Luxemburg Pharmaceuticals as distributor for Xerclear™
in Israel
Medivir AB (OMX: MVIR), the research-based speciality pharmaceutical
company focused on infectious diseases, is today pleased to announce
the appointment of Luxembourg Pharmaceuticals Ltd, as the exclusive
distributor for Xerclear™, Medivir's marketed and innovative treatment
for recurrent cold sores, in Israel and the Palestinian Authority.
Under the terms of the agreement, Luxembourg Pharmaceuticals Ltd., a
subsidiary of The Lapidot Group, a leading healthcare corporation based
in Israel, will be responsible for obtaining the regulatory approvals,
and for marketing, sales and distribution of Medivir's cold sore product
in the territory. In consideration of the rights granted to Luxembourg
Pharmaceuticals Ltd., Medivir will receive revenues from Xerclear™ sales
according to an undisclosed profit sharing scheme.
Commenting on the announcement Ron Long, Chief Executive Officer of
Medivir AB, said: “We are pleased to announce yet another distribution
partner for Xerclear™. We are convinced that Luxembourg Pharmaceuticals
Ltd. is an excellent partner for us in this territory.”
“We are pleased to be working with Medivir to distribute this important
product in our local market”, added Mr Ilan Lapidot, President and CEO,
Luxembourg Pharmaceuticals Ltd.
For more information about Medivir, please contact:
Medivir (www.medivir.se)
Rein Piir, CFO & VP Investor Relations
Office: +46 8 546 831 23Mobile: +46 708 537 292
M:CommunicationsMary-Jane Elliott / Emma
ThompsonMedivir@mcomgroup.com (Medivir@mcomgroup.com) +44(0)20 7920
2330
About Xerclear™
Xerclear™ (Xerese™ in the USA) - a patented combination of 5% acyclovir
and 1% hydrocortisone in Medivir's proprietary cream formulation - is a
topical product for the treatment of recurrent herpes labialis. The
indication text as approved by FDA, states “Xerclear™ is indicated for
the early treatment of recurrent herpes labialis (cold sores) to reduce
the likelihood of ulcerative cold sores and to shorten the lesion
healing time in adults and adolecents (12 years of age and older)”.
Xerclear™ is the first topical product that in controlled clinical
trials has been shown to significantly (P<0.0001 vs. placebo) reduce the
development of ulcerative lesions during a cold sore episode.
About cold sores
Recurrent herpes labialis (cold sores) is a common infection that
affects one-third of the population in the Western world resulting in
around 600 million episodes per year with 57 million people having 3 or
more episodes per year. The great majority of cases are caused by herpes
simplex virus type 1 (HSV-1). Unlike most viruses, the cold sore virus
is not completely eliminated by the body's immune response. Instead it
establishes a chronic, latent and life-long infection in sensory
ganglia. At a later date, the virus may be reactivated and travel back
to the skin - often around the mouth and nose - to trigger a clinical
episode of recurrent herpes labialis. The virus is reactivated by
factors like sunlight and stress.
Products based on antiviral substances such as aciclovir, penciclovir,
famciclovir and valaciclovir are the most commonly used treatment
options. The market for topical treatment of herpes infections in Israel
is estimated at USD 1.5 million, and in the USA and Europe at USD 230
million and USD 170 million, respectively.
About Medivir
Medivir is a research-based specialty pharmaceutical company focused on
the development of high-value treatments for infectious diseases.
Medivir has world class expertise in polymerase and protease drug
targets and drug development. Medivir has a strong R&D portfolio and has
recently launched its first product, an innovative treatment for cold
sores.
Xerese™/Xerclear™ is a treatment for cold sores, which has been approved
in both the US and Europe. It is partnered with GSK to be sold OTC in
Europe and Russia and by Meda in North America. Medivir have retained
the Rx rights for Xerclear™ in Sweden and Finland.
Medivir's key pipeline asset, TMC435, a protease inhibitor, is in Phase
2b clinical development for Hepatitis C and is partnered with Tibotec
Pharmaceuticals.
About Luxembourg Pharmaceuticals
Luxembourg Pharmaceuticals Ltd., a subsidiary of The Lapidot Group, a
privately held corporation based in Caesarea, Israel. Luxembourg
Pharmaceuticals has been a leading Israeli health care company since
1930 and exclusive Israeli importer and distributor for major
pharmaceutical companies' products including Alcon, B.Braun, ApoPharma,
and Piedmont Pharmaceuticals. Luxembourg is active in various healthcare
segments such as Ophthalmology, Women's Health, Haematology, Pediatrics
and OTC. Luxembourg maintains valuable relationships with the medical
community and operates as a fully integrated company in terms of sales,
marketing, logistics and regulatory affairs.
For more information about Medivir, please visit the Company's website:
www.medivir.se (http://www.medivir.se/)
Medivir appoints Luxemburg Pharmaceuticals as distributor for Xerclear™ in Israel
| Source: Medivir AB